<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496845</url>
  </required_header>
  <id_info>
    <org_study_id>VL#FIA3-30 #002</org_study_id>
    <nct_id>NCT02496845</nct_id>
  </id_info>
  <brief_title>Safety and Clinical Efficacy of Local Topical Treatment for Erectile Dysfunction</brief_title>
  <official_title>An Open Label Randomized Study to Examine the Safety and Clinical Efficacy of Local Topical Dual Active Preparation for Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VasoLead (2012) Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VasoLead (2012) Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      VL#FIA3-30 is a preparation intended for topical use, applied on the penis, for the treatment
      of ED.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VasoLead's preparation to treat erectile dysfunction (ED), VL#FIA3-30, is composed of 2
      active pharmaceutical ingredients, both act as vasodilators via different mechanisms. Both
      are currently used orally in the USA and Europe for the treatment of hypertension, angina
      pectoris and other diseases.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a aeasure of safety and tolerability of topical VL#FIA3-30 applied on the penis</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase the score level of the Erection Hardness Score (EHS) index</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase points of the International Index of Erectile Function-Erectile Function (IIEF-EF) score</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant increase of Flow Mediated Dilation (FMD) parameters</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase the total ED inventory of Treatment Satisfaction (EDITS) score</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of patient/Investigator satisfaction VAS score</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase the total score of the Quality of Erection Questionnaire (QEQ)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase the total score of the modified Quality of Erection Questionnaire (mQEQ)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical treatment and PK. Administration of VL#FIA3-30 (dual administration of MH30-01 &amp; IS045-01)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Groups B, C, D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual topical biweekly administration and intraurethral. Triple topical weekly administration. Multiple topical administration. Administration of VL#FIA3-30 (dual administration of MH30-01 &amp; IS045-01)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VL#FIA3-30</intervention_name>
    <description>Vasoactive dual treatment (MH30-01 &amp; IS045-01)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Groups B, C, D</arm_group_label>
    <other_name>Transdermal application</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent.

          -  ED for more than six months in duration.

          -  IIEF-EF domain score at baseline from 11 to 19 .

          -  Willingness for a minimum of two sexual attempts during the short period of this
             study.

          -  At least 50% unsuccessful sexual intercourse for 4 attempts on 4 different days.

          -  A stable heterosexual relationship with the same partner for more than six months.

          -  Age 25 to 75 years old.

        Exclusion Criteria:

          -  Neurological pathology;

          -  Prior radical prostatectomy;

          -  Any unstable medical or psychiatric condition, spinal cord injury, or penile
             anatomical abnormalities;

          -  Clinically significant chronic hematological disease;

          -  Cardiovascular conditions that prevent sexual activity (CHF or severe coronary artery
             disease);

          -  History of myocardial infarction, stroke, or life-threatening arrhythmia within 6
             months prior to enrollment into the study;

          -  Use of anti-androgens, or oral or injectable androgens;

          -  Documented hypotension (BP below 100 systolic or 70 diastolic) or known orthostatic
             hypotension;

          -  Routine use of more than 2 antihypertensive medications;

          -  Use of oral nitrates within 3 months prior to enrollment into the study;

          -  Cancer within the last 3 years;

          -  Documented allergic reaction;

          -  Investigators impression for patient non-compliance;

          -  Hepatic or renal failure;

          -  History of HIV, hepatitis B, hepatitis C;

          -  Is an immediate family member of personnel directly affiliated with the study at the
             investigative site, or is personally directly affiliated with the study at the
             investigative site;

          -  Subject has taken any investigational medication within 30 days prior of entry into
             the study

          -  Employed by VasoLead (2012) Ltd.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gruenwald Ilan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tami Bar, Dr.</last_name>
    <phone>+972 (0) 54 7510042</phone>
    <email>baret@isdn.net.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ilan Gruenwald, Prof.</last_name>
      <phone>+972 (0)4 7772819</phone>
      <email>i_gruenwald@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>July 13, 2015</last_update_submitted>
  <last_update_submitted_qc>July 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

